Total Payments
$5,187
2024 Payments
$828.15
Companies
30
Transactions
230
Medicare Patients
1,560
Medicare Billing
$251,218
Payment Breakdown by Category
Food & Beverage$5,037 (97.1%)
Research$150.00 (2.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,037 | 229 | 97.1% |
| Unspecified | $150.00 | 1 | 2.9% |
Payments by Type
General
$5,037
229 transactions
Research
$150.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $2,149 | 80 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $632.39 | 27 | $0 (2024) |
| Lilly USA, LLC | $508.54 | 30 | $0 (2024) |
| Kyowa Kirin, Inc. | $186.42 | 4 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $179.00 | 11 | $0 (2019) |
| Amgen Inc. | $173.28 | 11 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $154.15 | 7 | $0 (2024) |
| Indivior Inc. | $150.00 | 1 | $0 (2020) |
| PFIZER INC. | $122.56 | 8 | $0 (2024) |
| Exact Sciences Corporation | $120.68 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $828.15 | 34 | AstraZeneca Pharmaceuticals LP ($253.43) |
| 2023 | $664.51 | 27 | Lilly USA, LLC ($224.06) |
| 2022 | $327.33 | 16 | Novo Nordisk Inc ($200.37) |
| 2021 | $313.83 | 8 | Novo Nordisk Inc ($229.57) |
| 2020 | $317.66 | 7 | Indivior Inc. ($150.00) |
| 2019 | $613.96 | 27 | Novo Nordisk Inc ($399.92) |
| 2018 | $627.83 | 41 | Novo Nordisk Inc ($364.73) |
| 2017 | $1,494 | 70 | Novo Nordisk Inc ($808.47) |
All Payment Transactions
230 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $20.24 | General |
| Category: Diabetes | ||||||
| 12/05/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $21.05 | General |
| Category: Diabetes | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $12.90 | General |
| Category: Respiratory | ||||||
| 11/07/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: Diabetes | ||||||
| 10/31/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: Respiratory | ||||||
| 10/28/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $13.12 | General |
| Category: Inflammation | ||||||
| 10/18/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $21.44 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.87 | General |
| Category: DIABETES | ||||||
| 10/14/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: Oncology | ||||||
| 10/10/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $20.53 | General |
| Category: Diabetes | ||||||
| 10/02/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $15.55 | General |
| Category: Respiratory | ||||||
| 09/17/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $22.08 | General |
| Category: Diabetes | ||||||
| 09/16/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $124.24 | General |
| Category: Respiratory | ||||||
| 09/12/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: Respiratory | ||||||
| 08/22/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 07/24/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $22.31 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 07/09/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: Diabetes | ||||||
| 06/13/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $13.70 | General |
| Category: Diabetes | ||||||
| 06/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: DIABETES | ||||||
| 05/28/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.84 | General |
| Category: Respiratory | ||||||
| 05/21/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: Oncology | ||||||
| 05/09/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $15.47 | General |
| Category: Respiratory | ||||||
| 05/07/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $15.18 | General |
| Category: Diabetes | ||||||
| 05/06/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: Inflammation | ||||||
| 04/30/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Quantitative Testing of Prescriber/Pharmacist Knowledge, Attitudes and Behavior about SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) or the Authorized Generic of SUBOXONE Sublingual Film (CIII) Safety and Use Information | Indivior Inc. | $150.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 427 | 1,066 | $159,350 | $68,374 |
| 2022 | 5 | 424 | 1,013 | $153,850 | $75,672 |
| 2021 | 5 | 372 | 598 | $94,975 | $51,176 |
| 2020 | 4 | 337 | 707 | $119,625 | $55,997 |
Total Patients
1,560
Total Services
3,384
Medicare Billing
$251,218
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 336 | 974 | $146,100 | $66,282 | 45.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 27 | 27 | $6,750 | $1,370 | 20.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 64 | 65 | $6,500 | $721.78 | 11.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 320 | 904 | $135,600 | $69,832 | 51.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 47 | 52 | $9,100 | $3,533 | 38.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 23 | 23 | $5,750 | $1,523 | 26.5% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 11 | 11 | $1,100 | $518.62 | 47.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 23 | 23 | $2,300 | $265.37 | 11.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 163 | 251 | $43,925 | $26,129 | 59.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 159 | 297 | $44,550 | $23,264 | 52.2% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 16 | 16 | $4,000 | $1,494 | 37.4% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 16 | 16 | $1,600 | $234.56 | 14.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 18 | 18 | $900.00 | $54.00 | 6.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 203 | 515 | $90,125 | $44,235 | 49.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 105 | 163 | $24,450 | $10,534 | 43.1% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 18 | 18 | $4,500 | $1,011 | 22.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 11 | 11 | $550.00 | $217.25 | 39.5% |
About Dr. Edward Levine, MD
Dr. Edward Levine, MD is a Primary Care healthcare provider based in Staten Island, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1689761926.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Edward Levine, MD has received a total of $5,187 in payments from pharmaceutical and medical device companies, with $828.15 received in 2024. These payments were reported across 230 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($5,037).
As a Medicare-enrolled provider, Levine has provided services to 1,560 Medicare beneficiaries, totaling 3,384 services with total Medicare billing of $251,218. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Primary Care
- Other Specialties Internal Medicine
- Location Staten Island, NY
- Active Since 10/06/2006
- Last Updated 03/15/2018
- Taxonomy Code 261QP2300X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1689761926
Products in Payments
- Tresiba (Drug) $683.98
- Victoza (Drug) $527.69
- Ozempic (Drug) $334.46
- FASENRA (Biological) $272.04
- TRULICITY (Drug) $258.88
- RYBELSUS (Drug) $219.07
- MOUNJARO (Drug) $214.28
- Saxenda (Drug) $200.40
- Crysvita (Drug) $186.42
- SYMBICORT (Drug) $174.67
- JANUVIA (Drug) $152.23
- BUPRENORPHINE AND NALOXONE (Drug) $150.00
- JARDIANCE (Drug) $121.08
- Cologuard Collection Kit (Device) $120.68
- Xultophy 100/3.6 (Drug) $117.53
- Austedo XR (Drug) $110.91
- FARXIGA (Drug) $89.91
- XIFAXAN (Drug) $85.71
- GVOKE HYPOPEN (Drug) $72.23
- Otezla (Drug) $68.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Primary Care Doctors in Staten Island
Miss. Kashan Singh
Primary Care — Payments: $838.10
Primary Care $838.10
Kertje Rubenstein
Primary Care — Payments: $200.24
Primary Care $200.24
Joy Stennett
Primary Care — Payments: $183.10
Primary Care $183.10
Rosa Miller
Primary Care — Payments: $146.00
Primary Care $146.00
Pui Man Sit, Np, NP
Primary Care — Payments: $38.73
Primary Care $38.73
Diana Coseglia-Danna, Rn, Hnp, Fnp, RN, HNP, FNP
Primary Care
Primary Care